# A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy

> **NCT03776032** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 320 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Darbepoetin alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03776032
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-09-14
- **Primary completion:** 2000-11-08
- **Final completion:** 2002-02-27
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2018-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03776032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03776032, "A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03776032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*